This is in agreement with previous studies showing a high rate of immunoexpression of HBME-1 in malignant thyroid tumors.[21, 22, 24] A study by Sack et al. concluded that HBME-1 positivity in FNA of thyroid nodules supports the diagnosis of carcinoma, and Nga et al. found that a panel of HBME-1 and CK19 is highly discriminatory in the diagnostic workup for PTC. This evidence concerns the gene KRT19 and carcinoma.